Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Peter Turcsanyi

6PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursHaematologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

Sort by Publication Date:
|May 12, 2026
Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.

|Mar 27, 2023
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).

Martin Špaček, Lukáš Smolej, Martin Šimkovič

|Aug 27, 2022
Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.

Anna Petrackova, Jakub Savara, Peter Turcsanyi

|Oct 13, 2021
Towards a Better Characterisation of Leukemic Cells in Chronic Lymphocytic Leukaemia: Cell-Size Heterogeneity Reflects Their Activation Status and Migratory Abilities.

Gayane Manukyan, Zuzana Mikulkova, Peter Turcsanyi

|Dec 06, 2020
External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score.

Lukáš Smolej, Peter Turcsányi, Zuzana Kubová

|Aug 18, 2020
High CXCR3 on Leukemic Cells Distinguishes <i>IgHV</i> <sup>mut</sup> from <i>IgHV</i> <sup>unmut</sup> in Chronic Lymphocytic Leukemia: Evidence from CD5<sup>high</sup> and CD5<sup>low</sup> Clones.

Gayane Manukyan, Tomas Papajik, Zuzana Mikulkova

Pageof 1

Frequent Collaborators

3 joint publications

Jakub Savara

3 joint publications

Eva Kriegova

2 joint publications

Lukáš Smolej

2 joint publications

Martin Špaček

1 joint publications

Gayane Manukyan

1 joint publications

Tomas Papajik

1 joint publications

Zuzana Mikulkova

1 joint publications

Renata Urbanova

1 joint publications

Veronika Smotkova Kraiczova

1 joint publications

Milos Kudelka

Frequent Collaborators

3 joint publications

Jakub Savara

3 joint publications

Eva Kriegova

2 joint publications

Lukáš Smolej

2 joint publications

Martin Špaček